Orlistat and weight loss support for uric acid control in gout with obesity
Tests orlistat plus weight loss support in adults with gout and obesity.
Plain-language title generated from the registry record
Registry title: Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT
Key facts
- Where
- Shenyang, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with gout who are obese and have high blood uric acid. It tests orlistat plus a weight loss program against placebo for 24 weeks.
- Age
- 18 to 70 years
- Sex
- Men and women can join
- Disease stage
- Gout meeting the 2015 ACR/EULAR classification criteria, with BMI of 28 kg/m² or more and serum uric acid of 480 μmol/L or more
- Biomarker or test result
- Serum uric acid of 480 μmol/L or more
Main reasons for not taking part
- Reasons that rule out orlistat or other gout medicines
- Severe liver or kidney problems
- Severe allergy or bad reaction to the study drugs
- Pregnant or breastfeeding women
- Cancer, or gout caused by another condition
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07326839, who can take part
Where in China
- General Hospital of Northern Theater Command, PLAShenyang, ChinaContact: Ping Li, Ph DNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- XueMei Guo
- Trial code
- NCT07326839
- Record updated
- 8 January 2026
- Original description
A total of 120 obese gout patients were included in a 24-week double-blind randomized controlled design. The intervention group received orlistat 120 mg tid + UTL + individualized diet-exercise-behavioral reinforcement weight loss program, while the control group received a placebo + UTL + standard recommendations. The primary endpoint was the rate of achieving serum uric acid levels <360 μmol/L at 24 weeks; secondary endpoints included the proportion of weight loss ≥5%, frequency of gout attacks, and inflammatory indicators such as CRP and IL-1β; the activity of AMPK in PBMCs and the expression of HIF1α and NLRP3 inflammasome-related proteins were also assessed.Read full original descriptionShow less
Optimization of Blood Uric Acid Control in Obese Gout Patients by Orlistat-Mediated Metabolic Remodeling and Intensive Weight Management: A Randomized Controlled Trial
A total of 120 obese gout patients were included in a 24-week double-blind randomized controlled design. The intervention group received orlistat 120 mg tid + UTL + individualized diet-exercise-behavioral reinforcement weight loss program, while the control group received a placebo + UTL + standard recommendations. The primary endpoint was the rate of achieving serum uric acid levels <360 μmol/L at 24 weeks; secondary endpoints included the proportion of weight loss ≥5%, frequency of gout attacks, and inflammatory indicators such as CRP and IL-1β; the activity of AMPK in PBMCs and the expression of HIF1α and NLRP3 inflammasome-related proteins were also assessed.
Inclusion: Meeting the 2015 ACR/EULAR classification criteria for gout; Age 18-70 years; BMI ≥28 kg/m²; Serum uric acid ≥480 μmol/L; Willing and able to comply with the study protocol.
Exclusion: Contraindications to orlistat or other gout medications; History of severe allergy or adverse reactions to study drugs; Malignancy; Severe hepatic or renal dysfunction; Pregnant or lactating women; Secondary gout; Poor compliance or inability to cooperate; Participation in other clinical trials within the last 3 months.